Back to News
Market Impact: 0.15
Coherus Oncology, Inc. Reports 75% Confirmed ORR in First-Line ESCC Patients from Tagmokitug Interim Clinical Data
Source: Nasdaq
Healthcare & Biotech
Coherus Oncology announced interim clinical data from its TREGCHECK™ development program, evaluating investigational cytolytic CCR8 antibody tagmokitug in combination with toripalimab. The supplied article text ends before reporting the data or any results, so the clinical significance and market direction cannot be determined.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- ATEC Q3 2026 slides show profitability surge despite execution gaps
- West Pharma earnings show it's more than a GLP-1 play. Why we see more upside
- Linde delivers a good quarter and puts in a fix for an overhang on the stock
- Aspen Neuroscience prices IPO at $15 per share
- Aspen Neuroscience prices IPO at $15 per share on Nasdaq